Not yet recruiting
Study Comparing Neoadjuvant Versus Adjuvant Stereotactic Radiotherapy of Brain Metastases
NCT07437820· GCS Ramsay Santé pour l'Enseignement et la Recherche· Source
Contact: Philippe METELLUS, MD
Recruiting
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
NCT07554339· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
NCT07264075· Phase 3· Groupe Oncologie Radiotherapie Tete et Cou· Source
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
NCT06276465· Phase 3· UNICANCER· Source
Active, not recruiting
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
NCT06305754· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698· Hamilton Health Sciences Corporation· Source
Contact: Alexis Mechulan, MD (principal investigator)
Recruiting
Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis
NCT05476991· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Active, not recruiting
Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax
NCT05617963· Phase 2· UNICANCER· Source
Active, not recruiting
French eCLIPs™ Efficacy and Safety Investigation
NCT05330897· Evasc Medical Systems Corp.· Source
Active, not recruiting
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
NCT04624204· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
NCT04380636· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Safety and Efficacy of Silk Vista and Silk Vista Baby Flow Diverter for Intracranial Aneurysm Treatment
NCT04034810· Balt Extrusion· Source
Recruiting
PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer
2024-512173-27-00· Phase 3· Unicancer· Source
Active, not recruiting
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT03833154· Phase 3· AstraZeneca· Source
Active, not recruiting
Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck
2024-513206-65-00· Phase 3· Groupe Oncologie Radiotherapie Tete Cou· Source
Active, not recruiting
Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices
NCT03366545· Biotronik SE & Co. KG· Source
Active, not recruiting
Adjuvant immunotherapy after salvage surgery in head and neck squamous cell carcinoma: phase 2 trial evaluating the efficacy and the toxicity of nivolumab alone, and of the combination nivolumab and ipilimumab
2024-516810-39-00· Phase 2· Institut Gustave Roussy· Source
Active, not recruiting
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer
NCT03774732· Phase 3· UNICANCER· Source
Active, not recruiting
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
NCT02531516· Phase 3· Aragon Pharmaceuticals, Inc.· Source
Active, not recruiting
A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
NCT01952223· Phase 3· UNICANCER· Source